Genzyme Corp. diskutieren

Kaufenswert

Genzyme Corporation operates as a biotechnology company worldwide. It operates through five segments: Renal, Therapeutics, Transplant, Biosurgery, and Genetics. The Renal segment develops, manufactures, and distributes products for patients suffering from renal diseases, including chronic renal failure. This segment offers Renagel, a phosphate binder for the control of serum phosphorus in patients with chronic kidney disease (CKD) on hemodialysis; and Hectorol vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism in patients with stages 3 and 4 CKD, and in patients with stage 5 CKD on dialysis. The Therapeutics segment provides Cerezyme/Ceredase, an enzyme replacement therapy for the treatment of Gaucher disease; Fabrazyme, a recombinant form of the human enzyme alpha-galactosidase for the treatment of Fabry disease; Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with thyroid cancer; Myozyme therapy for Pompe disease; and Aldurazyme, a recombinant form of the human enzyme alpha-L-iduronidase to treat mucopolysaccharidosis I. The Transplant segment offers Thymoglobulin, a polyclonal antibody that suppresses immune cells responsible for acute organ rejection in transplant patients. The Biosurgery segment markets Synvisc, a biomaterial used to treat the pain associated with osteoarthritis of the knee; and Sepra products for preventing adhesions following various surgical procedures in the body. The Genetics segment provides reproductive testing services, diagnostic services for reproductive and oncology markets, and genetic counseling services. It has a collaboration agreement with PTC Therapeutics, Inc. to develop and commercialize PTC124 for the treatment of genetic disorders due to nonsense mutations. The company was founded in 1981 and is based in Cambridge, Massachusetts.

Durchbruch in MS-Forschung?

http://de.reuters.com/article/worldNews/idDEBEE49M03E20081023

Ein zur Behandlung von Leukämie entwickeltes Medikament scheint britischen Forschern zufolge die Krankheit Multiple Sklerose (MS) im frühen Stadium stoppen und verlorengegangene Funktionen wiederherstellen zu können.
Es gehe um das Mittel Alemtuzumab der Firmen Bayer und Genzyme, sagte der Neurologe Alasdair Cole von der Universität Cambridge am Mittwochabend der Nachrichtenagentur Reuters. Eine über drei Jahre andauernde Studie habe erstmals eine Langzeit-Verbesserung der Behinderungen gezeigt.

Man kann nur hoffen, dass die weitere Studien Erfolg zeigen. Zulassung des Medikaments könnte in 3-4 Jahren erfolgen.

Genzyme

Leicht abgebeben. Sollte jetzt wieder anziehen.                                                                                         

Potential

Die Aktie hat Potential auf mindestens 45 Euro zu steigen. Sie eignet sich für nicht so spekulative Anleger.